National Institute for Health Research (NIHR) Birmingham Liver Biomedical Research Centre (BRC), Institute of Immunology and Immunotherapy, University of Birmingham, UK; Liver Unit, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, UK.
Liver Unit, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, UK.
J Hepatol. 2017 Nov;67(5):957-965. doi: 10.1016/j.jhep.2017.06.027. Epub 2017 Jul 8.
BACKGROUND & AIM: Primary sclerosing cholangitis (PSC) is a progressive fibro-inflammatory cholangiopathy for which liver transplantation is the only life-extending intervention. These patients may benefit from accepting liver donation after circulatory death (DCD), however their subsequent outcome is unknown. The aim of this study was to determine the clinical impact of using DCD liver grafts in patients specifically undergoing transplantation for PSC.
Clinical outcomes were prospectively evaluated in PSC patients undergoing transplantation from 2006 to 2016 stratified by donor type (DCD, n=35 vs. donation after brainstem death [DBD], n=108).
In liver transplantation for PSC; operating time, days requiring critical care support, total ventilator days, incidence of acute kidney injury, need for renal replacement therapy (RRT) or total days requiring RRT were not significantly different between DCD vs. DBD recipients. Although the incidence of ischaemic-type biliary lesions was greater in the DCD group (incidence rate [IR]: 4.4 vs. 0 cases/100-patient-years; p<0.001) there was no increased risk of post-transplant biliary strictures overall (hazard ratio [HR]: 1.20, 0.58-2.46; p=0.624), or in sub-analysis specific to anastomotic strictures or recurrent PSC, between donor types. Graft loss and mortality rates were not significantly different following transplantation with DCD vs. DBD livers (IR: 3.6 vs. 3.1 cases/100-patient-years, p=0.34; and 3.9 vs. 4.7, p=0.6; respectively). DCD liver transplantation in PSC did not impart a heightened risk of graft loss (HR: 1.69, 0.58-4.95, p=0.341) or patient mortality (0.75, 0.25-2.21, p=0.598).
Transplantation with DCD (vs. DBD) livers in PSC patients does not impact graft loss or patient survival. In an era of organ shortage, DCD grafts represent a viable therapeutic option for liver transplantation in PSC patients. Lay summary: This study examines the impact of liver transplantation in primary sclerosing cholangitis (PSC) with organs donated after circulatory death (DCD), compared to donation after brainstem death (DBD). We show that in appropriately selected patients, the outcomes for DCD transplantation mirror those using DBD livers, with no significant differences in complication rate, patient survival or transplanted liver survival. In an era of organ shortage and increasing wait-list times, DCD livers represent a potential treatment option for transplantation in PSC.
原发性硬化性胆管炎(PSC)是一种进行性纤维炎症性胆管病,肝移植是唯一延长生命的干预措施。这些患者可能受益于接受死后循环(DCD)捐献的肝脏,但他们的后续结果尚不清楚。本研究的目的是确定在专门接受 PSC 移植的患者中使用 DCD 肝移植物的临床影响。
对 2006 年至 2016 年期间按供体类型(DCD,n=35 与脑死亡后捐献 [DBD],n=108)分层的 PSC 患者进行前瞻性评估。
在 PSC 肝移植中;手术时间、需要重症监护支持的天数、总呼吸机天数、急性肾损伤发生率、需要肾脏替代治疗(RRT)或总需要 RRT 的天数在 DCD 与 DBD 受者之间无显著差异。尽管 DCD 组的缺血性胆道病变发生率较高(发生率[IR]:4.4 与 0 例/100 患者年;p<0.001),但总体上并没有增加移植后胆道狭窄的风险(风险比[HR]:1.20,0.58-2.46;p=0.624),或者在供体类型特异性分析中,吻合口狭窄或复发性 PSC 也没有增加风险。DCD 与 DBD 肝脏移植后的移植物失效率和死亡率无显著差异(IR:3.6 与 3.1 例/100 患者年,p=0.34;3.9 与 4.7,p=0.6)。DCD 肝移植在 PSC 中并没有增加移植物失效率(HR:1.69,0.58-4.95,p=0.341)或患者死亡率(0.75,0.25-2.21,p=0.598)的风险。
在 PSC 患者中,使用 DCD(与 DBD)肝脏进行移植不会影响移植物失效率或患者生存率。在器官短缺的时代,DCD 供体为 PSC 患者的肝移植提供了一种可行的治疗选择。
非专业人士请谨慎阅读译文,如有需要请寻求专业人士的帮助。